Pliant Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
Pliant Therapeutics, Inc. filed a Form 8-K dated September 14, 2022, reporting corporate governance actions. The filing does not contain quarterly or annual financial results and does not establish a financial reporting period.
Financial Metrics and Liquidity
The filing provides no revenue, profit, cash flow, margin, debt, liquidity, or other operating financial metrics. It also provides no financial statements or guidance.
Material Changes
- Effective September 14, 2022, the Board appointed Dr. Katharine Knobil to a newly created director seat with a term expiring at the 2025 annual meeting.
- Dr. Knobil was appointed to the Board’s Research and Development Committee and was determined to be independent under applicable SEC and Nasdaq standards.
- Dr. Knobil will receive a prorated annual cash retainer of $39,000 and an option to purchase 30,000 common shares. The option vests in substantially equal monthly installments over three years, subject to continued Board service.
- The Company entered into its standard indemnification agreement with Dr. Knobil. The filing states that no related transaction requires disclosure under Item 404(a) of Regulation S-K.
- The Board approved amended and restated bylaws effective September 14, 2022. Changes address shareholder nomination and proposal procedures, shareholder meeting administration, and emergency procedures when a Board or committee quorum cannot readily be convened.
Guidance, Risks, and Unusual Items
No management guidance, outlook, contingencies, operational risks, or unusual financial items are disclosed. The principal matters are the appointment-related compensation and the revised governance provisions.
Important Facts to Verify
- Review Exhibit 3.1 for the complete text of the Second Amended and Restated Bylaws.
- Confirm the terms, exercise price, and accounting treatment of the 30,000-share director option in subsequent filings.
- Verify the prorated director retainer and any additional committee or equity compensation under the Company’s non-employee director compensation arrangements.
- Review subsequent proxy statements and periodic reports for the effect of the new director appointment and bylaws on governance disclosures.